Proximal embolic protection during carotid stenting: current devices and outcomes

Related Experiment Video

Updated: May 16, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

S C Kiang1, B G De Rubertis

  • 1Division of Vascular Surgery, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA. skiang@mednet.ucla.edu

The Journal of Cardiovascular Surgery
|December 5, 2012
PubMed

Insights

Proximal protection devices (PPD) offer superior outcomes for carotid angioplasty and stenting (CAS) compared to distal embolic protection (EPD), reducing adverse neurologic events. This review details PPD vs. EPD techniques and outcomes.

Area of Science:

  • Vascular Surgery
  • Interventional Cardiology
  • Neurology

Background:

  • Carotid angioplasty and stenting (CAS) is a key treatment for high-risk patients needing carotid endarterectomy (CEA).
  • Embolic protection devices (EPDs) reduce neurologic events during CAS.
  • Proximal protection devices (PPDs) show better outcomes than other EPDs at 30 days.

Purpose of the Study:

  • To compare distal embolic protection (EPD) and proximal embolic protection devices (PPD) in CAS.
  • To analyze procedural techniques, device pros and cons, and clinical outcomes.

Main Methods:

  • Review of prospective and retrospective clinical studies.
  • Comparison of device-specific procedural techniques.
  • Analysis of safety and efficacy outcome data.

Main Results:

  • Proximal protection devices (PPDs) demonstrate superior outcomes regarding adverse events at 30 days compared to distal EPDs.
  • Detailed comparison of procedural nuances and device limitations between PPD and EPD strategies.
  • Synthesis of clinical data highlighting PPD advantages.

Conclusions:

  • Proximal protection devices (PPDs) represent an advancement in embolic protection during CAS.
  • PPDs offer improved safety profiles and clinical outcomes compared to distal EPDs.
  • Further research may solidify PPDs as the preferred embolic protection strategy in CAS.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...